Clarke, Caroline S. http://orcid.org/0000-0002-4676-1257
Duffy, Larisa
Lewis, Glyn
Freemantle, Nick
Gilbody, Simon
Kendrick, Tony
Kessler, David
King, Michael
Lanham, Paul
Mangin, Derelie
Moore, Michael
Nazareth, Irwin
Wiles, Nicola
Marston, Louise
Hunter, Rachael Maree
Clinical trials referenced in this document:
Documents that mention this clinical trial
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT (Results)
https://doi.org/10.3310/hta25690
Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study
https://doi.org/10.1007/s40258-021-00693-x
Funding for this research was provided by:
Health Technology Assessment Programme (HTA 13/115/48, 14/0647)
Article History
Accepted: 19 October 2021
First Online: 8 November 2021
Change Date: 11 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40258-021-00708-7
Declarations
:
: The research was funded by the NIHR health technology assessment (HTA) Programme (HTA 13/115/48; 14/0647). This study was also supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
: TK received Grants from NIHR during the conduct of the study. RH, NW and MM received Grants from NIHR HTA during the conduct of the study. GL received grants from UCL during the conduct of the study and personal fees from Fortitude Law, outside the submitted work. NF has received personal fees from ALK, Allergan, Aimmune, AstraZeneca, MSD, Ipsen, Sanofi Aventis, Novo Nordisk, Grifols, Vertex and Abbott Singapore and grants from the European Association of Cardiothoracic Surgery, outside the submitted work. CSC, LD, SG, DK, MK, PL, DM, IN and LM have no conflicts of interest that are directly relevant to the content of this article.
: De-identified individual participant data and analytical code will be available from the authors to bona fide investigators for research projects that have been approved by independent review committees, after signing a data sharing agreement with the study sponsor (University College London, London, UK).
: Ethical approval was obtained from the National Research Ethics Service committee, East of England, Cambridge South (ref.: 16/EE/0032). Clinical trial authorisation was given by the MHRA. The trial sponsor was University College London. The trial was registered: EudraCT number 2015-004210-26; protocol number 14/0647 (version 7.0); Controlled Trials ISRCTN Registry, ISRCTN15969819.
: All study participants provided written informed consent before participating in the trial.
: CSC was lead author, and wrote the first draft of the article. CSC and RH planned and conducted the economic analyses. All authors were involved in formulating the overall research question, including economic aspects, and designing and conducting the study. PL was patient and public involvement collaborator. CSC, RH, LM, NF, GL and LD designed the economic data collection instruments. LD managed the data collection. LD and GL managed the trial. CSC, LM and LD were involved in data cleaning. CSC, RH and LM analysed the data. SG, TK, NW and DK were involved in participant recruitment. GL, IN, MK, DK, NW, SG, NF, RH, TK and MM were co-applicants on the funding application. All authors contributed to and approved the final manuscript.